The grant will also support a new initiative at the UVA Cancer Center to facilitate discussions between cancer survivors, caregivers, and researchers to improve cancer treatment strategies.

Focused ultrasound (FUS) technology allows for non-invasive treatment options that target tumors with greater precision, potentially reducing side effects and improving patient outcomes.

Dr. Natasha D. Sheybani of the University of Virginia has been awarded a $5.5 million grant from the Department of Defense to enhance breast cancer treatments through focused sound wave technology.

UVA has a strong history in focused ultrasound research, previously gaining FDA approvals for its use in treating conditions like Parkinson's disease.

The research could lead to significant improvements in patient outcomes by targeting tumors more effectively while minimizing damage to surrounding healthy tissue.

Sheybani is the first recipient from UVA to receive the Breast Cancer Research Program Era of Hope Scholar Award, recognizing her exceptional potential in cancer research.

Amy Bouton, a professor emerita at UVA, praised Sheybani for solidifying her position as a rising star in breast cancer research and bringing distinction to UVA.

FUS can create pathways through tumor barriers, guide treatments directly to cancer cells, and activate specialized drugs at precise locations, improving therapeutic effectiveness.

Dr. Sheybani's research explores how therapeutic soundwaves can stimulate the immune system to better recognize and combat cancer cells.

This initiative is part of a broader effort in Charlottesville to advance cancer therapies through the use of focused ultrasound technology.

Her vision is to create a new era of personalized, non-invasive cancer care that utilizes sound waves to empower patients with safer treatment options.

UVA Cancer Center is recognized as a comprehensive cancer center by the National Cancer Institute, being one of only 57 in the U.S.